Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833629 | PMC |
| http://dx.doi.org/10.1016/j.arteri.2020.12.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Atherogenic dyslipemia: the other pandemic, associated with diabesity.
Clin Investig Arterioscler
October 2021
Non-HDL cholesterol as a therapeutic goal.
Clin Investig Arterioscler
December 2019
Grupo de Trabajo sobre la Dislipidemia Aterogénica de la Sociedad Española de Arteriosclerosis, España; Unidad de Lípidos y Riesgo Vascular, Servicio de Medicina Interna, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, España; Institut d'Investigació Biomèdica de Bellvitge (Idibell), Centre d'Investigació Biomèdica en Xarxa-Fisiopatologia de l'Obesitat i la Nutrició (CiberObn), L'Hospitalet de Llobregat, Barcelona, España.
Although cholesterol linked to low-density lipoproteins (c-LDL) is well established as a risk factor for cardiovascular disease, there is often a more complex dyslipidaemia pattern that contributes to the formation of atherosclerotic plaque. Non-HDL cholesterol (c-NO-HDL) is used to estimate the total amount of atherogenic lipoproteins in plasma, some of which are not usually determined in daily clinical practice. c-NO-HDL is easily calculated from the subtraction of total plasma cholesterol from the cholesterol content carried by high density lipoproteins.
View Article and Find Full Text PDFHypoglycemic and Hypolipemic Effects of a New Lecithin Formulation of Bergamot Polyphenolic Fraction: A Double Blind, Randomized, Placebo- Controlled Study.
Endocr Metab Immune Disord Drug Targets
June 2019
Research and Development Unit, Indena S.p.A., Milan, Italy.
Objective: Hyperlipemia represents an independent risk factor in the development of atherosclerosis in patients undergoing type 2 diabetes mellitus (DM). Moreover, the pharmacological treatment of dyslipemia in patients undergoing type 2 DM (e.g.
View Article and Find Full Text PDFConsensus document on the management of the atherogenic dyslipidaemia of the Spanish Society of Arteriosclerosis.
Clin Investig Arterioscler
September 2017
Servicio de Medicina Interna, Hospital de Bellvitge, CIBERobn, Fipec, Universidad de Barcelona, Idibell, Hospitalet de Llobregat, Barcelona, España.
Positioning document and summary of recommendations recently published by the Working Group on Atherogenic Dyslipemia of the Spanish Society of Arteriosclerosis and by the European Society of Arteriosclerosis.
View Article and Find Full Text PDFPrevalence of Atherogenic Dyslipidemia in Spanish Hypertensive Patients and Its Relationship With Blood Pressure Control and Silent Organ Damage.
Rev Esp Cardiol (Engl Ed)
July 2015
Servicio de Medicina Interna, Hospital de Bellvitge, Universidad de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
Introduction And Objectives: To assess the prevalence of atherogenic dyslipidemia in hypertensive patients and its relationship with risk profile and blood pressure control.
Methods: The study included 24 351 hypertensive patients from the Spanish Ambulatory Blood Pressure Monitoring Registry. Atherogenic dyslipidemia was defined as the presence of hypertriglyceridemia (> 150mg/dL) and low levels of high-density lipoprotein cholesterol (< 40mg/dL in men and < 46mg/dL in women).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!